ANDREONE, Pietro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.475
AS - Asia 11.485
EU - Europa 7.608
SA - Sud America 1.908
AF - Africa 267
OC - Oceania 39
Continente sconosciuto - Info sul continente non disponibili 17
Totale 45.799
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.180
SG - Singapore 3.972
HK - Hong Kong 2.774
CN - Cina 2.640
GB - Regno Unito 1.723
BR - Brasile 1.521
SE - Svezia 1.051
FI - Finlandia 932
IT - Italia 901
VN - Vietnam 773
RU - Federazione Russa 693
DE - Germania 556
BG - Bulgaria 359
PL - Polonia 335
FR - Francia 232
TR - Turchia 197
ID - Indonesia 189
KR - Corea 184
AR - Argentina 182
IN - India 143
UA - Ucraina 137
CA - Canada 136
NL - Olanda 125
JP - Giappone 111
ZA - Sudafrica 109
AT - Austria 100
MX - Messico 100
BD - Bangladesh 91
LT - Lituania 72
ES - Italia 65
IE - Irlanda 64
IQ - Iraq 57
EC - Ecuador 54
CZ - Repubblica Ceca 45
EG - Egitto 45
AE - Emirati Arabi Uniti 43
CO - Colombia 37
MA - Marocco 37
BE - Belgio 36
SA - Arabia Saudita 33
RO - Romania 31
PK - Pakistan 30
UZ - Uzbekistan 30
CL - Cile 29
PY - Paraguay 26
AU - Australia 25
MY - Malesia 21
VE - Venezuela 21
IL - Israele 20
JO - Giordania 20
TN - Tunisia 20
IR - Iran 19
PE - Perù 18
KE - Kenya 17
GR - Grecia 16
KZ - Kazakistan 15
NO - Norvegia 15
A2 - ???statistics.table.value.countryCode.A2??? 14
PH - Filippine 14
CH - Svizzera 13
AL - Albania 12
AZ - Azerbaigian 12
KG - Kirghizistan 12
NP - Nepal 12
PT - Portogallo 12
UY - Uruguay 12
DO - Repubblica Dominicana 11
MK - Macedonia 11
NZ - Nuova Zelanda 11
DZ - Algeria 10
LV - Lettonia 10
HN - Honduras 9
MD - Moldavia 9
DK - Danimarca 8
LB - Libano 8
CR - Costa Rica 7
ET - Etiopia 7
GE - Georgia 7
BH - Bahrain 6
BO - Bolivia 6
BY - Bielorussia 6
EE - Estonia 6
HU - Ungheria 6
LA - Repubblica Popolare Democratica del Laos 6
RS - Serbia 6
SK - Slovacchia (Repubblica Slovacca) 6
KH - Cambogia 5
OM - Oman 5
TH - Thailandia 5
AM - Armenia 4
BW - Botswana 4
BZ - Belize 4
CY - Cipro 4
GD - Grenada 4
IS - Islanda 4
LK - Sri Lanka 4
LU - Lussemburgo 4
PA - Panama 4
QA - Qatar 4
TW - Taiwan 4
Totale 45.735
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.395
Hong Kong 2.743
Singapore 2.603
Fairfield 2.373
Ashburn 2.229
Chandler 2.080
London 972
Helsinki 890
Nyköping 857
Woodbridge 848
New York 836
Houston 779
Wilmington 753
Hefei 706
Seattle 698
Cambridge 625
Los Angeles 533
Ann Arbor 475
San Diego 467
Chicago 461
Beijing 440
Princeton 372
Sofia 356
The Dalles 352
Southend 344
Warsaw 321
Ho Chi Minh City 275
Moscow 217
San Jose 212
Salt Lake City 185
Buffalo 181
Shanghai 180
Jersey City 175
Hanoi 169
Modena 165
Seoul 164
Dearborn 152
Jacksonville 148
São Paulo 148
Jakarta 146
Council Bluffs 143
Redondo Beach 113
Dallas 112
Istanbul 91
Bremen 86
Tokyo 85
Johannesburg 72
Tampa 71
Denver 70
Milan 66
Munich 66
Vienna 66
Elk Grove Village 64
Orem 64
Frankfurt am Main 63
Phoenix 63
Dublin 59
Atlanta 57
Brooklyn 56
Norwalk 56
Rome 56
Bologna 54
Nuremberg 51
Viroflay 51
Izmir 48
Stockholm 48
Montreal 46
Rio de Janeiro 46
San Francisco 46
Kent 44
Kilburn 44
Augusta 43
Guangzhou 43
Toronto 43
Grafing 41
Sterling 41
Des Moines 40
Poplar 39
Amsterdam 38
Boston 37
San Mateo 36
Brussels 35
Detroit 35
Brno 33
Paris 33
Curitiba 32
Da Nang 32
Biên Hòa 31
Newark 31
Chennai 30
Eugene 30
Philadelphia 30
Haiphong 29
Mexico City 29
Chiswick 28
Groningen 27
Lancaster 27
Lauterbourg 27
Belo Horizonte 26
Boardman 26
Totale 33.054
Salva come PNG Salva come JPEG
Nome #
Non-alcoholic steatohepatitis and liver transplantation 500
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 360
Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times 358
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 331
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 295
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 288
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 287
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 285
Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes 282
De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients 272
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV 272
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 270
A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. 265
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 262
Missed treatment in an Italian HBV infected patients cohort: HBV RER 258
From current status to optimization of HCV treatment: Recommendations from an expert panel 254
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 247
Treatment of nonalcoholic steatohepatitis in adults: present and future 242
Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study 233
Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials 231
Molecular and functional characterization of CD133+ stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 230
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals 225
Global multi-stakeholder endorsement of the MAFLD definition 222
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 222
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” Study. 219
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 214
Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C 213
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 212
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 210
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results 208
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 207
Adaptive response in Hepatitis B virus infection 205
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 205
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group 201
Characteristics of hepatocellular carcinoma in Italy 200
Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives 196
Update on Alcohol and Viral Hepatitis 195
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 185
Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report 184
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study 182
Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients 182
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 178
Gross pathologic types of hepatocellular carcinoma in Italy. 175
Liver Stiffness measurments using Fibroscan after three months of IFN-based antiviral therapy is unlikely to predict viral response in cirrhotic patients 174
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 173
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” 173
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 173
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study 173
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 173
ABT-450: A novel agent for the treatment of CHC genotype 1: Focus on treatment-experienced patients 171
Transjugular intrahepatic portosystemic shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: a real-life, case-control study 169
Grazoprevir/elbasvir fixed-dose combination for hepatitis C 169
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 166
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 164
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: The Bagnacavallo Study 163
A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices 162
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 162
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives 161
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 160
Clinical and serological profile of primary biliary cirrhosis in men 160
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 160
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis 160
Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study 159
Alcohol and viral hepatitis: a mini-review 158
Genetic characterization of adult-onset cryptogenic cholestasis: a prospective multicentre study of 233 patients 157
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C 156
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C 156
Working together to tackle HCV infection: Ombitasvir/paritaprevir/ritonavir and dasabuvir combination 155
An in-depth psychosocial and biochemical evaluation in transplant recipients for alcoholic liver disease should be planned 154
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation 154
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 153
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients 152
Chronic hepatitis B: Are we close to a cure? 152
A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis 152
Indomethacin increases 2′,5′-oligoadenylate synthetase release by cultured liver tissue of patients with HCV chronic active hepatitis 151
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation 149
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 149
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 148
Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft 148
Central pontine myelinolysis secondary to glycemic variability in type 1 diabetes: a case report and a systematic review of the literature 147
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis 147
Virological Treatment Monitoring for Chronic Hepatitis B 146
Long-term antiviral treatment for recurrent hepatitis C after liver transplantation 146
Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods 146
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence 145
CD 133+ stem cells for the treatment of end stage liver disease 145
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis 144
Frailty after Liver Transplantation: A Complex Unexplored Issue 143
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation 143
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs 143
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 142
Treatments for hbv: A glimpse into the future 142
Familial intrahepatic cholestasis: New and wide perspectives 141
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study 141
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis 141
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 141
La fibrosi epatica: aggiornamenti su fisiopatologia, diagnosi e prognosi 140
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 139
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis 139
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 139
Totale 19.231
Salva come PNG Salva come JPEG
Categoria #
all - tutte 269.711
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 269.711
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.022 0 0 0 0 0 0 285 158 1.347 142 954 136
2021/20225.712 823 485 224 244 116 343 259 413 702 635 802 666
2022/20235.217 696 568 387 500 607 793 72 540 688 31 204 131
2023/20243.483 133 234 153 334 874 178 194 505 99 72 161 546
2024/202512.345 463 84 65 962 2.405 1.716 518 929 1.506 944 1.111 1.642
2025/202613.714 1.254 771 1.937 2.630 3.300 2.823 999 0 0 0 0 0
Totale 46.320